期刊文献+

临床药师参与1例头孢他啶致抗生素脑病患者治疗药物监测 被引量:4

Therapeutic Drug Monitoring in a Antibiotic Encepha-lopathy Patient induced by Ceftazidime Involved by Clinical Pharmacists
下载PDF
导出
摘要 目的:探究治疗药物监测(TDM)在诊治及预防头孢他啶致抗生素脑病的作用。方法:临床药师从分析头孢他啶致抗生素脑病发生的原因和机制,通过对患者TDM透析前后的血药浓度,评价患者症状的改善和血药浓度的变化间关系;佐证1例老年肾衰竭患者头孢他啶致抗生素脑病发生原因。结果:治疗药物浓度监测可协助临床诊治头孢他啶所致抗生素脑病。结论:治疗药物浓度监测对诊治头孢他啶致抗生素脑病的临床可操作性强,在临床治疗中通过TDM以预防抗生素脑病的发生。 Objective: To explore the role of therapeutic drug monitoring(TDM) in the diagnosis and treatment of antibiotic encephalopathy patients induced by ceftazidime involved by clinical pharmacists. Methods: The causes and mechanisms of antibiotic encephalopathy induced by ceftazidime were analyzed by clinical pharmacists, and the relationship between the improvement of symptoms and the change of blood drug concentration was evaluated by analyzing the blood drug concentration of patients before and after TDM dialysis. The cause of antibiotic encephalopathy induced by ceftazidime in an elderly patient with renal failure was evaluated. Results: The TDM is effective in clinical diagnosis and treatment of antibiotic encephalopathy caused by ceftazidime. Conclusion: Therapeutic drug concentration monitoring and treatment of antibiotic encephalopathy is clinically operability and worthy of popularization and application. It is more important to prevent the occurrence of antibiotic encephalopathy through TDM.
作者 叶超 谢建勇 胡英 王朝晖 YE Chao;XIE Jian-yong;HU Ying;WANG Zhao-hui(Department of Pharmacy,Niugxiang people's Hospital Affiliated to Hu'nan University of TCM,Changsha 410600,China)
出处 《抗感染药学》 2020年第5期716-719,共4页 Anti-infection Pharmacy
关键词 抗生素脑病 头孢他啶 治疗药物监测(TDM) 临床药师 antibiotic encephalopathy ceftazidime therapeutic drug concentration monitoring clinical pharmacist
  • 相关文献

参考文献7

二级参考文献45

  • 1盛平,黄文硕.头孢他啶致老年肾功能不全患者的中枢神经系统不良反应分析[J].中国实用医药,2007,2(6):46-47. 被引量:20
  • 2楼丽君,翁源红.102例药物致中枢神经系统不良反应分析[J].海峡药学,2004,16(4):130-132. 被引量:6
  • 3夏东亚,郭涛,陈岩,秦海旭.高效液相色谱法测定头孢他啶血药浓度[J].解放军药学学报,2007,23(1):41-43. 被引量:9
  • 4黎磊石,刘志红主编.中国肾脏病学[M].北京:人民军医出版社,2008,1328-1338
  • 5Hoffler D, Koeppe P, Williams KJ. The pbarmacokinetics of ceftazidime in normal and impaired renal funetion[J].J Antimicrob Chemother, 1983,12:241-245.
  • 6Pasko MT, Beam TR, Spooner JA, et al. Safety and Dharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction[J]. J Antimicrob Chemother, 1985,15: 365-374.
  • 7Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics[J]. Clin Nephrol, 1985,24: 142-146.
  • 8Ferrara N, Abete P, Giordano M, et al. Neurotoxocity induced by cefepime in a very old hemodialysis patient [J]. Clia Nephrol, 2003,59:388-389.
  • 9Ohkawa M, Nakashima T, Shoda R, et al. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis[J]. Chemotherapy, 1985, 31: 410-416.
  • 10Lin MS, Wang LS, Huang JD. Single- and multiple-dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function[J]. J C]in Pharmacol, 1989,29:331-337.

共引文献39

同被引文献21

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部